Anixa Biosciences Inc reported clinical data from two early-stage programs at the Frontiers in Cancer Immunotherapy symposium hosted by the New York Academy of Sciences. The San Jose, California-based biotechnology firm outlined final Phase 1 results for its breast cancer vaccine, produced in collaboration with Cleveland Clinic, and provided an update on an ongoing Phase 1 study of its ovarian cancer CAR-T therapy, liraltagene autoleucel (lira-cel).
Breast cancer vaccine results
In the presentation, Anixa released the final Phase 1 dataset for the breast cancer vaccine. The company said all major primary endpoints for the study were met. According to the results disclosed, the vaccine induced protocol-defined immune responses in 74% of participants and was determined to be safe and well tolerated at the maximum tolerated dose.
Ovarian cancer CAR-T update
Anixa also presented data for lira-cel, its ovarian cancer CAR-T therapy, from an ongoing Phase 1 clinical trial being conducted in collaboration with Moffitt Cancer Center. The company highlighted survival observations from the study, noting that multiple patients had lived more than one year after receiving treatment.
Market reaction
Following the symposium presentation, Anixa shares declined in trading, falling 4% on Friday. The market movement reflected investor response to the clinical disclosures despite the positive endpoints and reported tolerability.
Key points
- Final Phase 1 data for Anixa’s breast cancer vaccine show all primary endpoints were met, with 74% of participants mounting protocol-defined immune responses and acceptable tolerability at the maximum tolerated dose.
- Ongoing Phase 1 data for lira-cel, the company’s ovarian cancer CAR-T therapy developed with Moffitt Cancer Center, include survival observations with multiple patients surviving more than one year post-treatment.
- The company presented both datasets at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy symposium; shares subsequently fell 4% in after-market trading.
Risks and uncertainties
- The ovarian cancer CAR-T program remains in an ongoing Phase 1 trial, which means additional data and follow-up are required before conclusions about efficacy or wider clinical benefit can be drawn - this uncertainty affects biotech and healthcare market segments.
- Market reaction to clinical updates can diverge from trial outcomes; despite positive Phase 1 vaccine endpoints, the stock fell, indicating investor sensitivity and short-term volatility in biotechnology equities.
The information presented reflected the company’s disclosures at the scientific meeting. No additional clinical claims, dates, or external commentary were provided beyond those summarized at the symposium.